Drug intelligence / Profile preview

IBI-60089

Development stage: Preclinical
Lead developer: EyePoint Pharmaceuticals
Modality: Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Ophthalmic

Overview

IBI-60089 is a preclinical-stage sustained-release formulation developed by Icon Bioscience (now EyePoint Pharmaceuticals) for the treatment of glaucoma. The candidate utilizes the proprietary Verisome drug delivery platform, which consists of a biodegradable, injectable liquid that forms a solid or semi-solid depot within the eye. This technology is designed to provide long-term, controlled release of a therapeutic agent to manage intraocular pressure, potentially offering a more convenient alternative to the daily topical eye drops typically required for glaucoma management.

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on IBI-60089.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI-60089.

Explore the full profile